TY - JOUR
T1 - A Pharmacological Chaperone Molecule Induces Cancer Cell Death by Restoring Tertiary DNA Structures in Mutant hTERT Promoters
AU - Kang, Hyun Jin
AU - Cui, Yunxi
AU - Yin, Holly
AU - Scheid, Amy
AU - Hendricks, William P.D.
AU - Schmidt, Jessica
AU - Sekulic, Aleksandar
AU - Kong, Deming
AU - Trent, Jeffrey M.
AU - Gokhale, Vijay
AU - Mao, Hanbin
AU - Hurley, Laurence H.
N1 - Funding Information:
We are grateful to Dr. David Bishop for preparing, proofreading, and editing the final version of the manuscript and figures. This research was supported by the National Science Foundation (CH-1609514 [partial support] and CHE-1415883 to H.M.) and the National Institutes of Health (5R01CA153821 and 1R01GM085585 to L.H.H.).
Publisher Copyright:
© 2016 American Chemical Society.
PY - 2016/10/19
Y1 - 2016/10/19
N2 - Activation of human telomerase reverse transcriptase (hTERT) is necessary for limitless replication in tumorigenesis. Whereas hTERT is transcriptionally silenced in normal cells, most tumor cells reactivate hTERT expression by alleviating transcriptional repression through diverse genetic and epigenetic mechanisms. Transcription-activating hTERT promoter mutations have been found to occur at high frequencies in multiple cancer types. These mutations have been shown to form new transcription factor binding sites that drive hTERT expression, but this model cannot fully account for differences in wild-type (WT) and mutant promoter activation and has not yet enabled a selective therapeutic strategy. Here, we demonstrate a novel mechanism by which promoter mutations activate hTERT transcription, which also sheds light on a unique therapeutic opportunity. Promoter mutations occur in a core promoter region that forms tertiary structures consisting of a pair of G-quadruplexes involved in transcriptional silencing. We show that promoter mutations exert a detrimental effect on the folding of one of these G-quadruplexes, resulting in a nonfunctional silencer element that alleviates transcriptional repression. We have also identified a small drug-like pharmacological chaperone (pharmacoperone) molecule, GTC365, that acts at an early step in the G-quadruplex folding pathway to redirect mutant promoter G-quadruplex misfolding, partially reinstate the correct folding pathway, and reduce hTERT activity through transcriptional repression. This transcription-mediated repression produces cancer cell death through multiple routes including both induction of apoptosis through inhibition of hTERT's role in regulating apoptosis-related proteins and induction of senescence by decreasing telomerase activity and telomere length. We demonstrate the selective therapeutic potential of this strategy in melanoma cells that overexpress hTERT.
AB - Activation of human telomerase reverse transcriptase (hTERT) is necessary for limitless replication in tumorigenesis. Whereas hTERT is transcriptionally silenced in normal cells, most tumor cells reactivate hTERT expression by alleviating transcriptional repression through diverse genetic and epigenetic mechanisms. Transcription-activating hTERT promoter mutations have been found to occur at high frequencies in multiple cancer types. These mutations have been shown to form new transcription factor binding sites that drive hTERT expression, but this model cannot fully account for differences in wild-type (WT) and mutant promoter activation and has not yet enabled a selective therapeutic strategy. Here, we demonstrate a novel mechanism by which promoter mutations activate hTERT transcription, which also sheds light on a unique therapeutic opportunity. Promoter mutations occur in a core promoter region that forms tertiary structures consisting of a pair of G-quadruplexes involved in transcriptional silencing. We show that promoter mutations exert a detrimental effect on the folding of one of these G-quadruplexes, resulting in a nonfunctional silencer element that alleviates transcriptional repression. We have also identified a small drug-like pharmacological chaperone (pharmacoperone) molecule, GTC365, that acts at an early step in the G-quadruplex folding pathway to redirect mutant promoter G-quadruplex misfolding, partially reinstate the correct folding pathway, and reduce hTERT activity through transcriptional repression. This transcription-mediated repression produces cancer cell death through multiple routes including both induction of apoptosis through inhibition of hTERT's role in regulating apoptosis-related proteins and induction of senescence by decreasing telomerase activity and telomere length. We demonstrate the selective therapeutic potential of this strategy in melanoma cells that overexpress hTERT.
UR - http://www.scopus.com/inward/record.url?scp=84992206944&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84992206944&partnerID=8YFLogxK
U2 - 10.1021/jacs.6b07598
DO - 10.1021/jacs.6b07598
M3 - Article
AN - SCOPUS:84992206944
SN - 0002-7863
VL - 138
SP - 13673
EP - 13692
JO - Journal of the American Chemical Society
JF - Journal of the American Chemical Society
IS - 41
ER -